In 1943 the first discription of familial idiopathic methemoglobinemia in the United Kingdom was reported in 2 members of one family. Five years later, Quentin Gibson correctly identified the pathway involved in the reduction of methemoglobin in the family, thereby describing the first hereditary trait involving a specific enzyme deficiency. Recessive congenital methemoglobinemia (RCM) is caused by deficiency of NADH-cytochrome b5 reductase. One of the original propositi with the Type I disorder has now been traced. He was found to be a compound heterozygote harboring 2 previously undescribed mutations in exon 9, a point mutation G873A predicting a G291D substitution, and a 3bp in-frame deletion of codon 255 (GAG) predicting loss of glycine. A brother and surviving sister are heterozygous, each bearing one of the mutations. Thirty-three different mutations have now been recorded for RCM. The original authors' optimism that RCM would provide material for future genetic studies has been amply justified.
Introduction
In an era dominated by functional genomics it is salutary to reflect that the first hereditary disorder involving an enzyme deficiency was discovered just over half a century ago by Quentin Gibson 1 . In 1943 Dr Deeny a general practitioner described two brothers, Russell and Fred Martin from Banbridge in Northern Ireland, who had a blue appearance 2 . When Russell was treated with the vitamin C he turned pink, and Dr Deeny assumed that he had corrected an underlying heart condition. However the cardiologists in Belfast were more sceptical and were unable to find any abnormality in either brother. The conundrum attracted the attention of the physiologist Henry
Barcroft who carried out a detailed study of Dr Deeny's cases during treatment and found raised levels of methemoglobin in two members of the Martin family 3 . Gibson correctly defined the pathway involved in the reduction of methemoglobin in the family and, in so doing he described the first hereditary trait involving a specific enzyme deficiency 1 .
The disorder recessive congenital methemoglobinemia (RCM: McKusick no 250800)
is caused by a deficiency of NADH-cytochrome b5 reductase (cytb5r: E.C.1.6.2.2).
Two forms of cytb5r are known, a soluble form and a membrane-bound membrane one, localised in different cellular compartments. The soluble form is present mainly in red cells 4 and is involved in the reduction of methemoglobin 5 . The membranebound form is found mainly in the endoplasmic reticulum, and outer mitochondrial membrane 6 where it participates in the desaturation and elongation of fatty acids, the biosynthesis of cholesterol and P-450-mediated drug metabolism. The cytb5r gene is 31 kb in length, contains nine exons and has been localised to chromosome 22q 13- qter. Both forms of the enzyme are generated from tissue-specific alternative We were curious to know the actual mutations involved in Gibson's landmark discovery, and eventually had the opportunity to analyse blood from one of the propositi, Fred, who had emigrated to Australia in 1968, and two surviving siblings.
Materials and Methods

Case history
The pedigree for the family originally reported by Deeny et al and Barcroft et al 2, 3 is shown in Figure 2 . The three surviving family members were available for study, one of the original propositi (#6, FM) who has RCM Type I, a brother (#3, BM) and a sister (#5, EH). Unfortunately, during the course of this study both Fred Martin and his brother BM died. 
Results and Discussion
The cytb5r activity, measured using the NADH-ferricyanide method 10 * was < 0. These two hitherto unidentified mutations in the family originally studied by Gibson bring to 33 the number of different mutations described in patients with RCM ( see Figure 3 ). Previously 15 mutations had been associated with the Type I disorder [12] [13] [14] [15] [16] [17] [18] [19] and 16 with Type II RCM 16, 19, [20] [21] [22] [23] [24] [25] [26] . Mutations have been found in all exons, except 1 and 1S. The mutations which cause exon skipping and those predicted to give truncated proteins with severe impairment of function have only been described in Type II except in one case where the child did not show neurologic abnormalities at the age of one year 18 . Figure 3 The location of the mutations reported to date in the cytb5r gene of patients with For
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Since the structure of cytb5r has recently been resolved by X-ray crystallography 27 it is now possible to interpret the effects of mutations on enzyme function. Although the two novel exon 9 mutations are located outside the FAD and NADH binding sites both would be expected to have a deleterious effect on enzyme activity (see Figure 4) .
Loss of L255 would affect the packed hydrophobic environment formed by I177, L206, A208, T237, M256, M278 and C283 and the presence of aspartic acid at codon 291 instead of the non-polar glycine would also lead to perturbation of the secondary structure. 
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For personal use only. on . by guest www.bloodjournal.org From Figure 4 The predicted translation, demarcation of the soluble and membrane forms and the location of the secondary structure elements of cytb5r. 
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